Trial Profile
Prospective study to investigate features and management of pyrexia observed in metastatic melanoma patients treated with dabrafenib and trametinib (CombiDT)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Dec 2015
Price :
$35
*
At a glance
- Drugs Dabrafenib (Primary) ; Trametinib (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- 06 Dec 2015 New trial record